Halozyme Therapeutics (HALO) PT Raised to $79 at TD Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Rating Summary:
15 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Join SI Premium – FREE
TD Cowen analyst Brendan Smith raised the price target on Halozyme Therapeutics (NASDAQ: HALO) to $79.00 (from $77.00) while maintaining a Buy rating.
The analyst comments: "Top/bottom line beat/raise in Q1 is near best-case scenario for HALO made even more impressive given broader biopharma headwinds. Strong royalties from Darzalex/Phesgo strength & Vyvgart Hytrulo's outperformance + raised FY25 guidance support new PT of $79 (+$2). We still see additional upside potential from ongoing launches, buybacks + MRK litigation, all of which reaffirm HALO as a top pick."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hagerty Inc. (HGTY) PT Raised to $20 at Oppenheimer
- Clorox (CLX) PT Raised to $88 at TD Cowen
- Arch Capital (ACGL) PT Raised to $106 at Keefe, Bruyette & Woods
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Cowen & Co, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
